Q2 FY2026 · ended Jun 30, 2026 · Revenue $207,898, +106.0% YoY · Filed Aug 14, 2026
60 Degrees Pharmaceuticals, Inc. (SXTP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $207,898 and a net loss of $2.3 million. Free cash flow was -$2.2 million. As of Jun 30, 2026 it held $1.0 million in cash and investments and $150,030 in total debt.
Revenue
$207,898
+106.0% vs year-ago quarter
Net income
$-2.26M
-30.6% vs year-ago quarter
Operating cash flow
$-2.23M
-53.9% vs year-ago quarter
Free cash flow
$-2.23M
-49.0% vs year-ago quarter
EPS
$-0.90
+82.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
3.52M
-14.3% vs year-ago quarter
Net cash
$872,576
Q2 FY2026
Operating margin
-774.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SXTP (Nasdaq), SXTPW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1946563
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $207,898 | $162,092 | $303,385 | $437,602 | $100,932 |
| Operating income | -$2.3M | -$2.1M | -$1.9M | -$2.3M | -$1.6M |
| Net income | -$2.3M | -$2.1M | -$1.4M | -$2.3M | -$1.7M |
| Diluted EPS | -$0.90 | -$1.28 | -$1.30 | -$0.66 | -$5.01 |
| Operating cash flow | -$2.2M | -$2.7M | -$1.7M | -$2.1M | -$1.5M |
| Free cash flow | -$2.2M | -$2.8M | -$1.8M | -$2.1M | -$1.5M |
| Total assets | $4.3M | $6.8M | $5.4M | $6.7M | $4.2M |
| Total liabilities | $1.8M | $2.0M | $2.0M | $2.3M | $1.8M |
| Stockholders' equity | $2.6M | $4.8M | $3.5M | $4.4M | $2.4M |
| Cash and investments | $1.0M | $3.3M | $2.8M | $4.1M | $2.0M |
| Total debt | $150,030 | $150,030 | $152,775 | $150,000 | $150,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 222 60 Degrees Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.